JPY1,460.00
3.66% today
Tokyo, Nov 26, 07:15 am CET
ISIN
JP3435750009
Symbol
2413
Index

M3 Stock price

JPY1,465.50
-239.50 14.05% 1M
-79.50 5.15% 6M
-867.50 37.18% YTD
-906.50 38.22% 1Y
-4,645.50 76.02% 3Y
-1,524.50 50.99% 5Y
+439.00 42.77% 10Y
Tokyo, Closing price Tue, Nov 26 2024
+57.00 4.05%
ISIN
JP3435750009
Symbol
2413
Index

Key metrics

Market capitalization JPY956.42b
Enterprise Value JPY847.65b
P/E (TTM) P/E ratio 24.42
EV/Sales (TTM) EV/Sales 3.42
P/S ratio (TTM) P/S ratio 3.86
P/B ratio (TTM) P/B ratio 2.74
Dividend yield 1.35%
Last dividend (FY23) JPY19.00
Revenue growth (TTM) Revenue growth 5.94%
Revenue (TTM) Revenue JPY247.91b
EBIT (operating result TTM) EBIT JPY60.83b
Cash position JPY148.11b
EPS (TTM) EPS JPY57.67
P/E forward 24.45
P/S forward 3.48
EV/Sales forward 3.08
Show more

Is M3 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

M3 Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a M3 forecast:

4x Buy
31%
8x Hold
62%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a M3 forecast:

Buy
31%
Hold
62%
Sell
8%

Financial data from M3

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
247,907 247,907
6% 6%
100%
- Direct Costs 105,302 105,302
11% 11%
42%
142,605 142,605
3% 3%
58%
- Selling and Administrative Expenses 71,948 71,948
16% 16%
29%
- Research and Development Expense - -
-
-
70,657 70,657
8% 8%
29%
- Depreciation and Amortization 9,826 9,826
21% 21%
4%
EBIT (Operating Income) EBIT 60,831 60,831
11% 11%
25%
Net Profit 39,160 39,160
19% 19%
16%

In millions JPY.

Don't miss a Thing! We will send you all news about M3 directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

M3, Inc. engages in the provision of medical related services through the Internet. It operates through the following segments: Medical Portal, Evidence Solutions, Overseas, Clinical Platform, and Others. The Medical Portal segment provides the medical-related marketing support and research services. The Evidence Solutions segment includes clinical research support business, medical clinical trials management, and management support business. The Overseas segment offers marketing support and research services for medical-related firms in the United States, the United Kingdom, and South Korea. The Clinical Platform segment engages in the development, sale and support of electronic medical records. The Others segment offers information services for medical institutions and prescription drug advertising business. The company was founded on September 29, 2000 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Itaru Tanimura
Employees 12,100
Founded 2000
Website corporate.m3.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today